Sana Biotechnology, Inc.
SANAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Sana Biotechnology, Inc. focuses on Biotechnology services and products. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. At a $697.5M market cap, Sana Biotechnology, Inc. ranks as a small-cap company within healthcare. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Market Cap
$697.5M
Beta
2.19
P/E (TTM)
—
P/E (Fwd)
-4.20
EPS (TTM)
$-0.75
EPS (Fwd)
$-0.56
ROE
-152.9%
ROA
-29.2%
Cash
$160.5M
Total Debt
$80.9M
Free CF
$4.1M
52W Change
-58.3%
Annual Financials
Cash vs Debt
Where SANA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SANA finished 29.66% below its 150-day moving average ($3.27) and 33.91% below its 200-day moving average ($3.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SANA overbought or oversold?
At the October 20, 2026 close, SANA's RSI(14) was 22.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Sana Biotechnology, Inc. holds $160.5M in cash against $80.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $4.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -152.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.19 means SANA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. No single metric tells the full story. Reviewing SANA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.